Fol­low­ing con­tro­ver­sial Aduhelm ap­proval, DC-based neu­rol­o­gy cen­ter bans Bio­gen rep­re­sen­ta­tives from its of­fices — re­port

CEO Michael Vounatsos con­fessed ear­li­er this month that Bio­gen was strug­gling to get its con­tro­ver­sial new Alzheimer’s drug Aduhelm off the ground, with some ma­jor health sys­tems re­fus­ing to ad­min­is­ter it.

Now, a DC-based med­ical cen­ter is tak­ing its small re­bel­lion against the drug’s ap­proval one step fur­ther.

The Neu­rol­o­gy Cen­ter has re­port­ed­ly banned all Bio­gen rep­re­sen­ta­tives from its sev­en DC-area of­fices, ac­cord­ing to a pho­to cir­cu­lat­ing on Twit­ter.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN